{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:07:01Z","timestamp":1793765221106,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08HL122528-01A1"],"award-info":[{"award-number":["K08HL122528-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL157414-01"],"award-info":[{"award-number":["R01HL157414-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA049605"],"award-info":[{"award-number":["P01 CA049605"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01 HL075462"],"award-info":[{"award-number":["P01 HL075462"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41409-022-01716-4","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T14:05:29Z","timestamp":1654005929000},"page":"1319-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial"],"prefix":"10.1038","volume":"57","author":[{"given":"Efthymia Iliana","family":"Matthaiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husham","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-243X","authenticated-orcid":false,"given":"Christian","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-3020","authenticated-orcid":false,"given":"Wayland","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-2944","authenticated-orcid":false,"given":"Clark","family":"Owyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulami","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Brondstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-9634","authenticated-orcid":false,"given":"Guang-Shing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-6504","authenticated-orcid":false,"given":"Joe L.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"1716_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","volume":"129","author":"KM Williams","year":"2017","unstructured":"Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129:448\u201355. https:\/\/doi.org\/10.1182\/blood-2016-08-693507","journal-title":"Blood"},{"key":"1716_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/bmt.2012.241","volume":"48","author":"A Bergeron","year":"2013","unstructured":"Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant. 2013;48:819\u201324. https:\/\/doi.org\/10.1038\/bmt.2012.241","journal-title":"Bone Marrow Transplant"},{"key":"1716_CR3","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1513\/AnnalsATS.201604-262OC","volume":"13","author":"GS Cheng","year":"2016","unstructured":"Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, et al. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant. Ann Am Thorac Soc. 2016;13:1932\u20139. https:\/\/doi.org\/10.1513\/AnnalsATS.201604-262OC","journal-title":"Ann Am Thorac Soc"},{"key":"1716_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","volume":"191","author":"A Bergeron","year":"2015","unstructured":"Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, et al. Budesonide\/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191:1242\u20139. https:\/\/doi.org\/10.1164\/rccm.201410-1818OC","journal-title":"Am J Respir Crit Care Med"},{"key":"1716_CR5","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr.","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1402582","journal-title":"N Engl J Med"},{"key":"1716_CR6","doi-asserted-by":"publisher","first-page":"e12482","DOI":"10.7759\/cureus.12482","volume":"13","author":"PV Shah","year":"2021","unstructured":"Shah PV, Balani P, Lopez AR, Nobleza CMN, Siddiqui M, Khan S. A review of pirfenidone as an anti-fibrotic in idiopathic pulmonary fibrosis and its probable role in other diseases. Cureus. 2021;13:e12482 https:\/\/doi.org\/10.7759\/cureus.12482","journal-title":"Cureus"},{"key":"1716_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","volume":"129","author":"J Du","year":"2017","unstructured":"Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. Blood. 2017;129:2570\u201380. https:\/\/doi.org\/10.1182\/blood-2017-01-758854","journal-title":"Blood"},{"key":"1716_CR8","doi-asserted-by":"publisher","first-page":"PA3923","DOI":"10.1183\/13993003.congress-2016.PA3923","volume":"48","author":"KE Hostettler Haack","year":"2016","unstructured":"Hostettler Haack KE, Halter J, Tamm M. Pirfenidone treatment in patients with bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Eur Respir J. 2016;48:PA3923 https:\/\/doi.org\/10.1183\/13993003.congress-2016.PA3923","journal-title":"Eur Respir J"},{"key":"1716_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.healun.2013.02.004","volume":"32","author":"F Ihle","year":"2013","unstructured":"Ihle F, von Wulffen W, Neurohr C. Pirfenidone: a potential therapy for progressive lung allograft dysfunction? J Heart Lung Transplant. 2013;32:574\u20135. https:\/\/doi.org\/10.1016\/j.healun.2013.02.004","journal-title":"J Heart Lung Transplant"},{"key":"1716_CR10","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1111\/ajt.12474","volume":"13","author":"R Vos","year":"2013","unstructured":"Vos R, Verleden SE, Ruttens D, Vandermeulen E, Yserbyt J, Dupont LJ, et al. Pirfenidone: a potential new therapy for restrictive allograft syndrome? Am J Transplant. 2013;13:3035\u201340. https:\/\/doi.org\/10.1111\/ajt.12474","journal-title":"Am J Transplant"},{"key":"1716_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401 e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"1716_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","volume":"22","author":"KM Williams","year":"2016","unstructured":"Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22:710\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.009","journal-title":"Biol Blood Marrow Transplant"},{"key":"1716_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/00008483-200511000-00011","volume":"25","author":"DH Kupferberg","year":"2005","unstructured":"Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil. 2005;25:370\u20137. https:\/\/doi.org\/10.1097\/00008483-200511000-00011","journal-title":"J Cardiopulm Rehabil"},{"key":"1716_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","volume":"8","author":"S Lee","year":"2002","unstructured":"Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:444\u201352. https:\/\/doi.org\/10.1053\/bbmt.2002.v8.pm12234170","journal-title":"Biol Blood Marrow Transplant"},{"key":"1716_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NM, O\u2019Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160\u20134. https:\/\/doi.org\/10.1136\/bmj.305.6846.160","journal-title":"BMJ"},{"key":"1716_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","volume":"104","author":"JJ Swigris","year":"2010","unstructured":"Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104:296\u2013304. https:\/\/doi.org\/10.1016\/j.rmed.2009.09.006","journal-title":"Respir Med"},{"key":"1716_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","volume":"26","author":"C Teh","year":"2020","unstructured":"Teh C, Onstad L, Lee SJ. Reliability and validity of the modified 7-day lee chronic graft-versus-host disease symptom scale. Biol Blood Marrow Transplant. 2020;26:562\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"1716_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","volume":"159","author":"JL Hankinson","year":"1999","unstructured":"Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179\u201387. https:\/\/doi.org\/10.1164\/ajrccm.159.1.9712108","journal-title":"Am J Respir Crit Care Med"},{"key":"1716_CR19","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9:e95192 https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"key":"1716_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S2213-2600(18)30185-1","volume":"6","author":"M Neighbors","year":"2018","unstructured":"Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respiratory Med. 2018;6:615\u201326. https:\/\/doi.org\/10.1016\/S2213-2600(18)30185-1","journal-title":"Lancet Respiratory Med"},{"key":"1716_CR21","doi-asserted-by":"publisher","first-page":"e0202167","DOI":"10.1371\/journal.pone.0202167","volume":"13","author":"Z Li","year":"2018","unstructured":"Li Z, Xie W, Liu T. Efficient feature selection and classification for microarray data. PLoS ONE. 2018;13:e0202167 https:\/\/doi.org\/10.1371\/journal.pone.0202167","journal-title":"PLoS ONE"},{"key":"1716_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1074\/mcp.M112.022566","volume":"12","author":"C Christin","year":"2013","unstructured":"Christin C, Hoefsloot HC, Smilde AK, Hoekman B, Suits F, Bischoff R, et al. A critical assessment of feature selection methods for biomarker discovery in clinical proteomics. Mol Cell Proteom. 2013;12:263\u201376. https:\/\/doi.org\/10.1074\/mcp.M112.022566","journal-title":"Mol Cell Proteom"},{"key":"1716_CR23","doi-asserted-by":"publisher","unstructured":"Cottin, V, Koschel, D, Gunther, A, Albera, C, Azuma, A, Skold, CM, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 4. https:\/\/doi.org\/10.1183\/23120541.00084-2018 (2018).","DOI":"10.1183\/23120541.00084-2018"},{"key":"1716_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/bbmt.2003.49999","volume":"9","author":"G Akpek","year":"2003","unstructured":"Akpek G, Chinratanalab W, Lee LA, Torbenson M, Hallick JP, Anders V, et al. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant. 2003;9:46\u201351. https:\/\/doi.org\/10.1053\/bbmt.2003.49999","journal-title":"Biol Blood Marrow Transplant"},{"key":"1716_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/bmt.2015.320","volume":"51","author":"A Im","year":"2016","unstructured":"Im A, Mitchell SA, Steinberg SM, Curtis L, Berger A, Baird K, et al. Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD. Bone Marrow Transplant. 2016;51:705\u201312. https:\/\/doi.org\/10.1038\/bmt.2015.320","journal-title":"Bone Marrow Transplant"},{"key":"1716_CR26","doi-asserted-by":"publisher","first-page":"e47024","DOI":"10.1371\/journal.pone.0047024","volume":"7","author":"C Jiang","year":"2012","unstructured":"Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS ONE. 2012;7:e47024 https:\/\/doi.org\/10.1371\/journal.pone.0047024","journal-title":"PLoS ONE"},{"key":"1716_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12072-020-10069-3","volume":"14","author":"JL Poo","year":"2020","unstructured":"Poo JL, Torre A, Aguilar-Ramirez JR, Cruz M, Mejia-Cuan L, Cerda E, et al. Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study. Hepatol Int. 2020;14:817\u201327. https:\/\/doi.org\/10.1007\/s12072-020-10069-3","journal-title":"Hepatol Int"},{"key":"1716_CR28","doi-asserted-by":"publisher","unstructured":"Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler KU, Albera, C. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J. 54. https:\/\/doi.org\/10.1183\/13993003.00399-2019 (2019).","DOI":"10.1183\/13993003.00399-2019"},{"key":"1716_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/eye.2017.21","volume":"31","author":"B Khanum","year":"2017","unstructured":"Khanum B, Guha R, Sur VP, Nandi S, Basak SK, Konar A, et al. Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Eye. 2017;31:1317\u201328. https:\/\/doi.org\/10.1038\/eye.2017.21","journal-title":"Eye"},{"key":"1716_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.lfs.2007.11.003","volume":"82","author":"S Nakayama","year":"2008","unstructured":"Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008;82:210\u20137. https:\/\/doi.org\/10.1016\/j.lfs.2007.11.003","journal-title":"Life Sci"},{"key":"1716_CR31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/ajt.15667","volume":"20","author":"JL Todd","year":"2020","unstructured":"Todd JL, Kelly FL, Nagler A, Banner K, Pavlisko EN, Belperio JA, et al. Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation. Am J Transplant. 2020;20:825\u201333. https:\/\/doi.org\/10.1111\/ajt.15667","journal-title":"Am J Transplant"},{"key":"1716_CR32","first-page":"11","volume":"7","author":"S Krishnan","year":"2007","unstructured":"Krishnan S, Goble JM, Frederick LA, James CD, Uhm JH, Kaufmann SH. et al. Inhibitory effect of pirfenidone on glioblastoma cell lines: implications for treatment of neurofibromatosis. J Appl Res. 2007;7:11","journal-title":"J Appl Res"},{"key":"1716_CR33","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/ajt.14295","volume":"17","author":"JR Greenland","year":"2017","unstructured":"Greenland JR, Sun H, Calabrese D, Chong T, Singer JP, Kukreja J, et al. HLA mismatching favoring host-versus-graft NK cell activity Via KIR3DL1 is associated with improved outcomes following lung transplantation. Am J Transplant. 2017;17:2192\u20139. https:\/\/doi.org\/10.1111\/ajt.14295","journal-title":"Am J Transplant"},{"key":"1716_CR34","doi-asserted-by":"publisher","first-page":"e2021005","DOI":"10.4084\/MJHID.2021.005","volume":"13","author":"X Fang","year":"2021","unstructured":"Fang X, Zhu X, Tang B, Song K, Yao W, Wan X, et al. Donor KIR3DL1\/receptor HLA-Bw4-80I combination reduces acute leukemia relapse after umbilical cord blood transplantation without in vitro T-cell depletion. Mediterr J Hematol Infect Dis. 2021;13:e2021005 https:\/\/doi.org\/10.4084\/MJHID.2021.005","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1716_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF00196692","volume":"428","author":"M Kasper","year":"1996","unstructured":"Kasper M, Lackie P, Haase M, Schuh D, Muller M. Immunolocalization of cathepsin D in pneumocytes of normal human lung and in pulmonary fibrosis. Virchows Arch. 1996;428:207\u201315. https:\/\/doi.org\/10.1007\/BF00196692","journal-title":"Virchows Arch"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01716-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T08:09:05Z","timestamp":1659600545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01716-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01716-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"25 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JH was supported by the National Institutes of Health (NIH) during the period that the study was conducted. GSC reports grants from NIH and the V Foundation during the study period. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}